{"id":"NCT02486406","sponsor":"AbbVie","briefTitle":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","officialTitle":"An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-10-28","primaryCompletion":"2020-11-19","completion":"2020-11-19","firstPosted":"2015-07-01","resultsPosted":"2021-10-05","lastUpdate":"2021-10-05"},"enrollment":64,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Infection"],"interventions":[{"type":"DRUG","name":"Ombitasvir/paritaprevir/ritonavir","otherNames":["Ombitasvir also known as ABT-267","Paritaprevir also known as ABT-450","Ombitsvir/paritaprevir/ritonavir also known as Viekirax"]},{"type":"DRUG","name":"Dasabuvir","otherNames":["Exviera","ABT-333"]},{"type":"DRUG","name":"Ribavirin","otherNames":[]},{"type":"DRUG","name":"Ombitasvir mini tablet","otherNames":["ABT-267"]},{"type":"DRUG","name":"Paritaprevir mini tablet","otherNames":["ABT-450"]},{"type":"DRUG","name":"Ritonavir mini tablet","otherNames":[]},{"type":"DRUG","name":"Dasabuvir mini tablet","otherNames":["Exviera","ABT-333"]},{"type":"DRUG","name":"Ribavirin solution","otherNames":[]}],"arms":[{"label":"Adult tablet, 12-17 yr, Part 1","type":"EXPERIMENTAL"},{"label":"Adult tablet, 12-17 yr, Part 2","type":"EXPERIMENTAL"},{"label":"Mini tablet, 9-11 yr, Part 1","type":"EXPERIMENTAL"},{"label":"Mini tablet, 3-8 yr, Part 1","type":"EXPERIMENTAL"}],"summary":"This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pediatric participants of ≥ 3 to 17 years of age.","primaryOutcome":{"measure":"Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV)","timeFrame":"At Week 2","effectByArm":[{"arm":"15 - 29 kg Body Weight","deltaMin":99.6,"sd":27},{"arm":"30 - 44 kg Body Weight","deltaMin":116,"sd":14},{"arm":"≥ 45 kg Body Weight","deltaMin":83.7,"sd":39}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":21,"countries":["United States","Belgium","Germany","Puerto Rico","Spain"]},"refs":{"pmids":["32451952"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Headache","Fatigue","Pyrexia","Nasopharyngitis","Upper respiratory tract infection"]}}